ASCO 2022

Conference Coverage

Primary Tumor Resection Provides No OS Benefit in Asymptomatic Colorectal Cancer With Unresectable Metastases

The data suggest that primary tumor resection does not improve overall survival, but chemotherapy does.

Factors Related to Adherence to Oral Multiple Myeloma Therapy

Researchers identified socioeconomic and demographic factors related to oral treatment adherence in patients with multiple myeloma.

GOC Program Improved Outcomes for Cancer Patients During COVID-19 Pandemic

The program was associated with significant reductions in patients’ length of stay in the ICU, ICU mortality, and in-hospital mortality.

Medicaid Expansion May Have Improved Access to Cancer Trials

The expansion of Medicaid eligibility was associated with a nearly 3-fold increase in the proportion of Medicaid-covered patients enrolled in cancer treatment trials.

Geriatric Screening and CARG Toxicity Assessment Tools Predict Adverse Outcomes

The G8 and CARG chemotherapy toxicity assessment tools were found to predict early hospitalization/ER visits and death in older patients with cancer.

Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation

Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.

High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer

Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.

Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer

Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.

LDCT Screening Tied to Lower Incidence of Advanced Lung Cancer

The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.

Camrelizumab, Apatinib, and Temozolomide Combo Produces Durable Responses in Acral Melanoma

The overall response rate was 66.7%, and the median duration of response was 17.5 months.

Treatment Advances for Metastatic Breast Cancer Tied to Decrease in Deaths

Among patients with ER+/HER2+ breast cancer, the median survival after distant recurrence increased from 2.3 years in 2000 to 4.8 years in 2019.

Acupuncture Improves Symptoms of Radiation-Induced Xerostomia in Head and Neck Cancer

Acupuncture was associated with improvements in symptoms and quality of life.

The Effect of Gender Bias in Surveys of Patients With Myeloproliferative Neoplasms

Gender balance in cancer surveys of patients with myeloproliferative neoplasms was found to have relatively little effect on survey outcomes.

Trabectedin No Better Than Physician’s Choice in Recurrent Ovarian Cancer

There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.

Rivoceranib Appears Active in Recurrent, Metastatic Adenoid Cystic Carcinoma

Rivoceranib produced responses whether or not patients had received prior treatment with a VEGFR TKI.

Toripalimab With Axitinib Active in Treatment-Naive Advanced Mucosal Melanoma

Patients were stratified by programmed death ligand 1 status and randomly and evenly assigned to 3 treatment groups.

Camrelizumab, Apatinib, Temozolomide Combination Is Efficacious for Acral Melanoma

In all, 32 patients had a response, translating to an ORR of 66.7%.

Triple Combination Active Against CNS Metastases of BRAF^V600-Mutated Melanoma

The 3-drug strategy combines targeted therapy against BRAF (vemurafenib) and MEK (cobimetinib), and immunotherapy (atezolizumab).

Neoadjuvant Pembrolizumab in Resectable Desmoplastic Melanoma Leads to High pCR Rate

The study population included patients aged 18 years and older who had histologically confirmed desmoplastic melanoma that was resectable.

Omitting Node Dissection, Adjuvant Therapy May Be Safe for Some With Stage III Melanoma

The estimated 2-year RFS rate for patients with MPR was 93.3% (95% CI, 87.2%-99.9%) after a median follow-up of 27.9 months.